Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsNeighborhood Health Plan RI ADHD formulary: Covera…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

    Drug formulary: ADHD/amphetamines coverage and requirements

    Customize your policy alerts

    Sign up for all Neighborhood Health Plan of Rhode Island policy alerts

    Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Portions of Neighborhood Health Plan of Rhode Island's prescription drug formulary covering ADHD/anti-narcolepsy/amphetamine class medications, tiers, and specific requirements (prior authorization, step therapy, quantity limits) for ACCESS and TRUST plan members effective January 1, 2026.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyDrug formulary: ADHD/amphetamines coverage and requirements
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain and document prior authorization for new starts of products listed as 'PA for new starts' (e.g., chewable lisdexamfetamine and selected branded stimulants).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-01-01formulary effective date for ACCESS/TRUST
    No copaymember cost-sharing
    PA / QL / STutilization controls common
    1/daytypical stimulant QL
    Age/QLopioid controls

    Formulary Coverage and Utilization Controls

    Formulary coverage conditions

    Covered when plan tier and utilization rules are met per formulary entries

    Formulary tier and pharmacy: Medication is covered when it is listed on the member's formulary at the assigned plan tier (e.g., Tier 1 or Tier 2) and the prescription is dispensed through a participating pharmacy.

    From formulary header and Requirements/Limits

    Utilization controls (PA, ST, QL)

    Coverage requires meeting the following utilization controls for listed formulations

    Utilization controls: For chewable lisdexamfetamine formulations, selected lisdexamfetamine capsule strengths, and VYVANSE chewable formulations: Step therapy (ST) may apply; Prior Authorization (PA) is required for new starts when indicated; Quantity Limits (QL) apply as specified (typical QL = 1 tab/cap every 1 day).QL = 1 per day

    See Requirements/Limits and Drug Name table

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyDrug formulary: ADHD/amphetamines coverage and requirements
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain and document prior authorization for new starts of products listed as 'PA for new starts' (e.g., chewable lisdexamfetamine and selected branded stimulants).
    SourceLink
    On This Page
    Formulary Coverage and Utilization ControlsCodes, Quantity Limits and ExamplesAuthorization, Documentation, and Denial RiskNew-Start Controls and Initiation RequirementsStep Therapy RequirementsQuantity Limits by Product and StrengthPolicy Background and ScopeGlossary and Abbreviations

    Per-product utilization management

    Coverage and utilization management rules in this section apply as listed per-product

    Per-product rules: Each listed drug line includes its formulary tier and any utilization management flags that must be met for coverage: Prior Authorization (PA) when indicated; Step Therapy (ST) when indicated; Quantity Limits (QL) as specified; Age limits where provided; OTC status where provided.

    See individual product rows for exact requirement combinations (e.g., 'ST, PA, QL (1 tab every 1 day); PA for new starts')

    General coverage condition

    Covered when drug-specific tier and utilization controls are met

    General requirement: Prescribed drug must be on the formulary and adhere to the utilization management requirements shown on the product line (PA, ST, QL, AGE, OTC) to be covered; supporting documentation must be provided where PA or diagnosis-based QL is indicated.

    See product rows for exact limits

    Opioid coverage criteria

    Opioid agents are subject to additional quantity and age controls

    Opioid quantity and age limits: Prescriptions for listed opioid products are subject to specified Quantity Limits (QL) and minimum age restrictions (AGE) where stated; claims exceeding QL or for patients outside age limits require prior authorization or will be denied.varies by product (see product line)

    Exceeding limits requires PA or may be denied

    Prior Authorization and Quantity Limits (selected agents)

    Coverage subject to plan-level utilization management for selected branded and specialty agents

    PA_and_QL_for_selected_drugs: Prior Authorization AND adherence to the specified Quantity Limits are required for selected branded and specialty drugs (examples shown: TRYVIO TAB 12.5MG, FIRDAPSE TAB 10MG, ONUREG, FRUZAQLA, INLYTA, LENVIMA).see QL per drug

    Requirements vary by product and strength; PA generally required for these agents

    Generic Tier 1 coverage

    Generic drugs and combination antihypertensives

    Generic_Tier1_coverage: Multiple generic antihypertensive combinations and other generic products are assigned to Tier 1 and generally have no additional utilization requirements specified in these product lines; some items note availability for 90-day fills.N/A

    See product lines for exceptions

    Oral oncology agents — PA and QL

    Antineoplastic oral agents

    Oral_oncology_PA_QL: Oral antineoplastics and targeted agents are listed with Prior Authorization (PA) and product-specific Quantity Limits (QL) (examples: ONUREG 14 tabs/28 days; FRUZAQLA 84 caps/28 days; INLYTA 8 or 4 tabs per day depending on strength; LENVIMA strength-specific caps/day).see product QL entries

    PA generally required for these agents

    The formulary lists ALLI CAP 60MG as an OTC product. As indicated in the drug table, OTC-designated items are presented without prescription utilization enforcement in this listing (Requirements/Limits = OTC). Providers should note that OTC designation means the formulary line does not apply the PA/QL controls shown for prescription agents in this section.

    Source: the formulary line for ALLI CAP 60MG shows Requirements/Limits = OTC, indicating over‑the‑counter status and exclusion from the prescription PA/QL enforcement described elsewhere in the drug list.

    Several formulations in the analgesic and related drug sections are explicitly identified as OTC (for example, naproxen sodium 220 mg). When a product is marked OTC in the Requirements/Limits field, it is listed as available over‑the‑counter and is not subject to the prescription utilization controls (PA, ST, QL) applied to prescription formulations in this document.

    Providers should confirm whether an OTC designation applies to the specific strength/formulation being prescribed; the formulary line for each product indicates the OTC status in the Requirements/Limits column.

    Within the extracted chunks there are no explicit formulary exclusion statements beyond the OTC designations noted for certain items. The generic antihypertensive and other generic lines in these chunks (Tier 1 entries) are listed with no Requirements/Limits annotations that would indicate specific exclusions.

    If a formal exclusion exists it is not present in these cited segments; coverage determinations should rely on the complete formulary lines and any separate exclusion schedules maintained by the plan.

    The reviewed chunks do not contain explicit 'not medically necessary' declarations for any listed products. Coverage stance in these segments is described as covered with criteria where PA, ST, QL, age limits, or OTC status are shown — but no items are labeled as not medically necessary in the cited text.

    For definitive not‑medically‑necessary determinations, refer to the full policy or exclusion sections outside these chunks; none are present in the provided excerpts.

    Codes, Quantity Limits and Examples

    Authorization, Documentation, and Denial Risk

    Prior Authorization

    Prior Authorization Required — general

    Prior Authorization (PA) is required for many specialty, branded, and certain generic products listed on the formulary. Failure to obtain PA when indicated may result in claim denial or delay. For products flagged as "PA for new starts", prescribers must document whether the member is a new start and supply supporting clinical justification.

    • Obtain PA for all drugs with the PA flag before dispensing; missing PA is a common denial trigger.
    • When a product is marked "PA for new starts", include documentation that the patient is initiating therapy and the medical indication.
    • Quantity limits (QL) shown on formulary entries must be respected; requests exceeding QL require prior clinical justification and are subject to denial.
    Prior Authorization

    PA and Quantity Limits for Biologics/Targeted Therapies

    Prior Authorization and quantity limits apply to many biologic and targeted therapies. Providers must document diagnosis and clinical rationale to meet PA and QL requirements.

    • Anti‑TNF, JAK inhibitors, interleukin agents and other biologics often require PA and have explicit QL (for example, ENBREL, RINVOQ, XELJANZ entries).
    • Quantity limits for some biologics are diagnosis‑based — include supporting diagnosis documentation when requesting PA.
    • Follow the specified QL (e.g., ENBREL: quantity limit based on diagnosis; RINVOQ: 12 mL/day for solution) when submitting requests.
    Step Therapy

    Step Therapy + Prior Authorization — selected products

    Step therapy (ST) is required for selected agents and may be coupled with PA. For products with ST, prior trials of preferred alternatives must be documented; failure to meet ST requirements can result in denial even when PA is obtained.

    • Combination inhalers such as BREO ELLIPTA, DULERA, and fluticasone‑furoate/vilanterol list ST and PA — document prior therapies and clinical rationale.
    • ST applies to multiple classes (e.g., select amphetamine products, some ADHD meds, antidiabetic combos, GLP‑1/GLP‑1‑related injectables).
    • When both ST and PA are required, demonstrate that ST criteria were met or provide justification for bypassing ST (e.g., intolerance or contraindication).
    Prior Authorization

    Product-specific PA and Quantity Limits (examples)

    Specific product groups require PA and have defined quantity limits or level‑based limits. Providers must follow these product‑specific rules when requesting authorization.

    • Methylphenidate transdermal patches (Daytrana generics): ST, PA, QL (1 patch/day); PA is required for new starts — document prior therapies and new‑start status.
    • Palforzia (peanut allergen immunotherapy) levels: PA required with level‑specific QL (level‑based caps or packets per day as listed).
    • Aminoglycosides: ARIKAYCE SUS and tobramycin nebulizer solution require PA; tobramycin nebu soln QL is 10 mL/day.
    • Ztalmy: PA and QL (1,100 mL every 30 days).
    • Xcopri: PA and QL specified per pack/strength (e.g., 1 tab/day for many packs) — include dosing regimen in request.
    Prior Authorization

    PA and QL for Oncology and Selected Specialty Agents

    Oncology and other specialty agents frequently list PA plus specific QL per strength or pack. Requests must include regimen details and diagnosis to support medical necessity.

    • Many antineoplastic and targeted oral agents require PA and list QL by strength or pack (examples include LENVIMA, VENCLEXTA, ONUREG, FRUZAQLA, XPOVIO).
    • TRYVIO and other specialty branded oncology agents require PA and have per‑day QL (e.g., TRYVIO 1 tab/day).
    • For oncology agents, include treatment intent, line of therapy, weight or BSA if dosing is weight‑based, and expected duration when requesting PA.
    Documentation Required

    Documentation Expectations and Denial Risk

    Documentation must accompany PA requests. Provide diagnosis, prior treatment history, age limits (when applicable), dosing schedule, and justification for exceptions or QL overrides.

    • Diagnosis‑required QL (e.g., ENBREL): include supporting diagnosis and relevant clinical notes.
    • Document age limits where specified (e.g., phenytoin chewable tablets have a maximum age indication); claims outside age limits may be denied.
    • For GLP‑1 agonists and antidiabetic injectables (e.g., MOUNJARO, OZEMPIC, RYBELSUS), include prior therapy trials and indicate if PA is for a new start.
    • TRYVIO and other branded agents: supply clinical documentation sufficient to support PA and adherence to the per‑day QL.
    • General PA documentation: medication history, rationale for chosen agent, recent labs or imaging if relevant, and notation whether member is a new start.
    Denial Risk

    Quantity and Age Limit Enforcement — denial triggers

    Quantity limits and age restrictions are actively enforced. Claims exceeding QL or falling outside age restrictions without adequate documentation are at high risk for denial.

    • Review formulary QL entries (examples: OTEZLA 55 tabs/28 days; HUMULIN R U‑500 QL; many oncology agents' tab/cap limits).
    • For drugs with explicit daily or per‑28‑day limits, include clinical justification for larger quantities when warranted.
    • Age limits (e.g., certain chewable formulations) must be documented; requests for patients outside the age range require medical justification.

    New-Start Controls and Initiation Requirements

    New start controls

    Requirements for new starts

    New start requirements: Prior authorization is required for new starts of specified products (examples include chewable lisdexamfetamine formulations and VYVANSE chewables). Step therapy and quantity limits also apply as listed on product rows.

    PA for new starts explicitly noted in Requirements/Limits

    OTEZLA initiation

    Brand PDE4 inhibitor initiation

    threshold":"55 tabs/28 days","note":"See product row for strength-specific QL","children":[]}

    PA requirement for new starts

    Prior authorization for new starts

    PA for new starts: Prior authorization is required for new starts of multiple specified agents across the formulary (examples include chewable lisdexamfetamine strengths, VYVANSE chewables, and certain GLP-1 receptor agonist pens such as MOUNJARO which note 'PA for new starts').

    Providers must document indication and new-start status when seeking PA

    Step Therapy Requirements

    ProductRequirement
    lisdexamfetamine dimesylate chew tab 10 mg (generic)ST, PA, QL (1 tab every 1 day); PA for new starts
    lisdexamfetamine dimesylate chew tab 20 mg (generic)ST, PA, QL (1 tab every 1 day); PA for new starts
    lisdexamfetamine dimesylate chew tab 30 mg (generic)ST, PA, QL (1 tab every 1 day); PA for new starts
    lisdexamfetamine dimesylate chew tab 40 mg (generic)ST, PA, QL (1 tab every 1 day); PA for new starts
    lisdexamfetamine dimesylate chew tab 50 mg (generic)ST, PA, QL (1 tab every 1 day); PA for new starts
    lisdexamfetamine dimesylate chew tab 60 mg (generic)ST, PA, QL (1 tab every 1 day); PA for new starts
    VYVANSE CHW 10 mg (brand)ST, PA, QL (1 tab every 1 day); PA for new starts
    VYVANSE CHW 20 mg (brand)ST, PA, QL (1 tab every 1 day); PA for new starts
    ProductRequirement
    AZSTARYS CAP 39.2-7.8 (brand)ST, PA, QL (1 cap every 1 day); PA for new starts (alternative listing: PA, QL 2 tabs every 1 day)
    AZSTARYS CAP 52.3-10 (brand)ST, PA, QL (1 cap every 1 day); PA for new starts (alternative listing: PA, QL 2 tabs every 1 day)
    QELBREE ER (QuilliChew CHW) 20/30/40 mg (brand)ST, PA, QL (1 tab every 1 day); PA for new starts
    AZSTARYS and select lisdexamfetamine chewable strengths (see product rows)ST applies; PA and QL as specified per strength; PA for new starts where listed
    ProductRequirement
    methylphenidate HCl tab ER osmotic release (e.g., CONCERTA) 54 mg (generic)Requirements vary by form; transdermal patches list ST, PA, QL (1 patch every 1 day); PA for new starts
    methylphenidate TD patch (Daytrana) 10/15/20/30 mg/9hr (generic)ST, PA, QL (1 patch every 1 day); PA for new starts
    QuilliChew CHW 20/30/40 mg ER (brand)ST, PA, QL (1 tab every 1 day); PA for new starts
    modafinil 100 mg and 200 mg (generic)QL (2 tabs every 1 day); ST not indicated
    ProductRequirement
    ARIKAYCE SUS (amikacin liposome inhalation suspension) (brand)PA (listed); ST noted for aminoglycoside class entries; PA for new starts as indicated
    tobramycin nebulizer solution 300 mg/5 mL (Kitabis Pak generic)ST, PA, QL (10 mL every 1 day); PA for new starts
    Adalimu- (adalimumab biosimilars/brands) injections (various presentations)ST, PA, QL (product-specific limits such as syringes per 28 days); PA required
    HADLIMA INJ 40/0.4 mL (brand)ST, PA, QL (1.6 mL every 28 days); PA required
    ProductRequirement
    acetaminophen chew tabs/liquid/susp (OTC-designated formulations)ST, PA, QL (29 tabs every 42 days) noted for these analgesic entries; OTC designation present
    selected non-opioid analgesics (e.g., ketorolac 10 mg) and other OTC itemsSome entries list ST in addition to PA and QL indicating step therapy may be required before coverage
    ProductRequirement
    BREO ELLIPTA (fluticasone furoate-vilanterol) and genericsST, PA, QL (1 inhaler every 30 days) indicated for fluticasone furoate-vilanterol formulations
    DULERA AER 50-5MCG / 100-5MCG / 200-5MCG (brand)ST, PA (listed); step therapy required prior to PA/coverage
    fluticasone furoate-vilanterol aero powd ba 100-25 mcg/act (generic)ST, PA, QL (1 inhaler every 30 days); PA required
    ProductRequirement
    FYCOMPA SUS 0.5 mg/mL (perampanel suspension) (brand)ST, PA, QL (8 mL every 1 day); PA for new starts
    perampanel tabs (2,4,6,8,10,12 mg) (generic of FYCOMPA)ST, PA, QL (strength-specific; many list 1 tab every 1 day or 2 tabs every 1 day); PA for new starts
    ProductRequirement
    TRINTELLIX TAB 5/10/20 mg (brand)ST, PA, QL (1 tab every 1 day); PA for new starts
    ProductRequirement
    alogliptin-metformin combinations (various strengths) (generic)ST, PA (step therapy plus prior authorization) as listed
    MOUNJARO INJ pens (various strengths) (brand)ST, PA, QL (4 pens every 28 days); PA for new starts
    JARDIANCE (empagliflozin) and selected SGLT2 combinationsST, PA, QL (1 tab every 1 day); PA for new starts where indicated
    OZEMPIC / RYBELSUS / other GLP-1 combinations (selected strengths)ST and PA indicated for many branded GLP-1 products; QL as specified per product
    ProductRequirement
    granisetron HCl tab 1 mg (generic)ST, PA indicated for some 5-HT3 agents (granisetron listed with ST, PA)
    ondansetron HCl oral solution / tabs (generic)Some ondansetron entries show QL; select agents show ST in Requirements/Limits field indicating step therapy may apply
    ProductRequirement
    eplerenone tab 25 mg / 50 mg (generic of INSPRA)ST, PA; PA for new starts (step therapy required prior to PA for new starts)
    TRYVIO TAB 12.5 mg (brand) - related listingPA, QL (1 tab every 1 day) noted in same section; eplerenone explicitly lists ST prior to PA for new starts

    Quantity Limits by Product and Strength

    inv-129: lisdexamfetamine (capsule and chewable formulations) — QL entries
    Lisdexamfetamine QL1 cap/tab every 1 day
    FormulationsApplies to capsules and chewable tablets across listed strengths
    Associated controlsST and PA often indicated for chewable strengths (PA for new starts)
    inv-130: lisdexamfetamine (caps & chew tabs) — 1 cap/tab every 1 day
    Quantity limit1 cap/tab every 1 day
    Applies toLisdexamfetamine capsules and chew tabs (multiple strengths)
    ReferenceSee product Requirements/Limits rows
    inv-131: WEGOVY, ZEPBOUND — 4 pens every 28 days
    WEGOVY / ZEPBOUND pen QL4 pens every 28 days
    Applies toWEGOVY and ZEPBOUND injectable pens across listed strengths
    AuthorizationPA required as indicated in product rows
    inv-132: WAKIX — 2 tabs every 1 day
    WAKIX QL2 tabs every 1 day
    ProductWAKIX (pitolisant) 4.45 mg
    RequirementPA and QL listed on product row
    inv-133: methylphenidate chew tabs (2.5,5,10 mg) — 3 tabs every 1 day; Age Max 17
    Chewable methylphenidate QL3 tabs every 1 day
    Age limitMax age 17
    Strengths2.5 mg, 5 mg, 10 mg chew tabs
    inv-134: methylphenidate solution (5 mg/5 mL; 10 mg/5 mL) — 30 mL every 1 day; Age Max 17
    Methylphenidate solution QL30 mL every 1 day
    Age limitMax 17
    Concentrations5 mg/5 mL and 10 mg/5 mL formulations listed
    inv-135: dexmethylphenidate ER caps — 1 cap every 1 day
    Dexmethylphenidate ER QL1 cap every 1 day
    Applies toMultiple ER strengths of dexmethylphenidate (Focalin XR generics)
    NotesSome strength rows also list PA and alternative QLs (2 tabs) mapped to 1 cap/day
    inv-136: methylphenidate TD patch (Daytrana) generics — 1 patch
    Daytrana patch QL1 patch every 1 day
    Applies toMethylphenidate TD patch (Daytrana) generics, multiple strengths
    ControlsST and PA noted; PA for new starts
    inv-137: modafinil 100 mg and 200 mg — 2 tabs
    Modafinil QL2 tabs every 1 day
    Strengths100 mg and 200 mg strengths listed with QL = 2/day
    Applies toModafinil (Provigil) generics/brands
    inv-138: Palforzia CAP levels — varies by level (examples provided)
    Palforzia QL variationsVaries by level (e.g., Escalation: 13 caps/day; Level 1: 3 caps/day; Level 2: 6 caps/day)
    Applies toPalforzia capsule levels and powder packet levels
    PAPA required for Palforzia products
    inv-139: tobramycin nebu soln 300 mg/5ml — 10 mL
    Tobramycin nebu soln QL10 mL every 1 day
    ProductTobramycin nebulizer solution 300 mg/5 mL (Kitabis Pak generic)
    AuthorizationST and PA indicated; PA required per product row
    inv-140: selected biologics QL examples — product-specific QL (adalimumab, Rinvoq, etc.)
    Biologics QL examplesProduct-specific QLs (e.g., adalimumab entries: 2 syringes every 28 days or 1.6–3.2 mL every 28 days; Rinvoq: 1 tab every day)
    ExamplesFASENRA, NUCALA, XOLAIR, Hadlima, Simponi, Rinvoq listed with PA and QL
    DocumentationDiagnosis-based QL may require supporting documentation for PA
    inv-141: NSAID examples QL/OTC status — celecoxib 400 mg; ketorolac; other NSAIDs
    NSAID examplesCelecoxib 400 mg: QL = 1 cap/day; Ketorolac: QL = 20 tabs every 30 days
    OTC statusSeveral NSAID formulations noted as OTC (e.g., naproxen 220 mg)
    Applies toSelected NSAID rows in Analgesics section
    inv-142: OTEZLA TAB 10/20/30 — 55 tabs every 28 days
    OTEZLA QL55 tabs every 28 days
    Strengths10/20/30 mg tablet formulations
    AuthorizationPA indicated in product row
    inv-143: FENTANYL TD PATCH 72HR — 10 patches
    Fentanyl TD patch QL10 patches every 30 days
    RangeApplies to multiple strengths of 72HR fentanyl patches
    ControlsPA and AGE minimums noted for opioid products
    inv-144: BUPRENORPHINE HCL SL TAB 2 MG — 12 tabs
    Buprenorphine SL tab QL12 tabs (2 mg) or 3 tabs (8 mg) every 1 day depending on strength
    ExampleBuprenorphine HCl SL tab 2 mg: QL 12 tabs every 1 day
    UseMAT products listed with QL in Requirements/Limits
    inv-145: FASENRA INJ 10MG/0.5 — 1 syringe
    FASENRA QL1 syringe every 56 days
    NUCALA QL1 syringe every 28 days (40 mg/0.4)
    XOLAIR QL2 pens or 2 syringes every 28 days (75/0.5)
    inv-146: NUCALA INJ 40MG/0.4 — 1 syringe
    NUCALA QL1 syringe every 28 days (40 mg/0.4)
    Other formsNUCALA 100 mg: 3 vials or 3 auto-injectors every 28 days
    PAPA listed for NUCALA formulations
    inv-147: XOLAIR INJ 75/0.5 — 2 pens or 2 syringes
    XOLAIR QL2 pens or 2 syringes every 28 days (75/0.5)
    Alternate strengthsXOLAIR 150 mg and 300 mg have higher QLs (8 pens or 4 pens every 28 days respectively)
    PAPA required for XOLAIR entries
    inv-148: budesonide inhalation susp — 4 mL
    Budesonide inhalation suspension QL4 mL every 1 day
    ProductsBudesonide inhalation suspension (Pulmicort generics) 0.5 mg/2 mL and 1 mg/2 mL
    Inhaler comparatorsSome inhalers have 1 inhaler every 30 days or 2 inhalers every 30 days limits
    inv-149: fluticasone propionate aero powder — 2 inhalers
    Fluticasone powder QL2 inhalers every 30 days (250 mcg/act)
    Other strengthsLower strengths often have 1 inhaler every 30 days limits
    ProductsFluticasone propionate aerosol powder (various strengths)
    inv-150: levalbuterol HCl nebu solutions — 90 mL
    Levalbuterol nebule QL90 mL every fill
    Applies toLevalbuterol HCl nebulizer solutions (various concentrations)
    Fill frequencyQL specified per fill rather than per day for nebulizer solutions
    inv-151: ELIQUIS ST P TAB 5MG — 75
    ELIQUIS ST P 5 mg QL75 tabs every 30 days
    ELIQUIS 2.5 mg QL2 tabs every 1 day
    Related DOACsRivaroxaban 2.5 mg: 2 tabs/day; Xarelto STAR 15/20 mg: 55 tabs/30 days
    inv-152: ELIQUIS TAB 2.5MG — 2
    ELIQUIS 2.5 mg QL2 tabs every 1 day
    UseApplies to apixaban low-dose tablets as listed
    Note30-day QLs also specified for other strengths
    inv-153: rivaroxaban tab 2.5 mg — 2
    Rivaroxaban 2.5 mg QL2 tabs every 1 day
    Applies toGeneric rivaroxaban 2.5 mg (Xarelto generic equivalence)
    ContextUsed for combination antithrombotic dosing per formulary
    inv-154: XARELTO STAR TAB 15/20MG — 55
    XARELTO STAR 15/20 QL55 tabs every 30 days
    XARELTO 10 mg QL1 tab every 1 day
    XARELTO 15 mg QL2 tabs every 1 day
    inv-155: XARELTO TAB 10MG — 1
    XARELTO 10 mg QL1 tab every 1 day
    UseTypically for prophylactic dosing post-procedure per product labeling
    NotesOther Xarelto strengths have different QLs
    inv-156: XARELTO TAB 15MG — 2
    XARELTO 15 mg QL2 tabs every 1 day
    Applies to15 mg strength product rows
    Related QLs15/20 STAR pack QL differs (55/30 days)
    inv-157: XARELTO TAB 20MG — 1
    XARELTO 20 mg QL1 tab every 1 day
    Applies to20 mg strength product rows
    NotesQLs vary by strength and pack
    inv-158: dabigatran etexilate caps — 2
    Dabigatran QL2 caps every 1 day
    Strengths75, 110, 150 mg strengths listed with QL 2/day
    ContextApplies to dabigatran etexilate capsule entries
    inv-159: FYCOMPA SUS 0.5MG/ML — 8
    FYCOMPA suspension QL8 mL every 1 day
    Perampanel tabs1-2 tabs/day depending on strength (PA for new starts)
    ControlsST and PA indicated for FYCOMPA products
    inv-160: perampanel tabs — 1-2
    Perampanel tabs QL1–2 tabs every 1 day depending on strength
    PA for new startsPA indicated for many perampanel entries
    Example strengths2 mg: 2/day; 4–12 mg: 1/day mapping noted
    inv-161: diazepam rectal gel delivery — 2
    Diazepam rectal gel QL2 kits per fill
    NAYZILAM / VALTOCONAYZILAM and VALTOCO: 5 boxes every 30 days
    Use caseSeizure rescue medications limited by QL per fill/30 days
    inv-162: NAYZILAM SPR 5MG — 5
    NAYZILAM QL5 boxes every 30 days
    VALTOCO QL5 boxes every 30 days (5,10,15,20 mg presentations)
    ContextBenzodiazepine rescue spray products listed with 30-day box limits
    inv-164: DIACOMIT CAP/PACK — 6
    DIACOMIT QL6 caps/pack per day
    EPIDIOLEX QL20 mL per day (100 mg/mL solution)
    FINTEPLA QL12 mL per day (2.2 mg/mL solution)
    inv-165: EPIDIOLEX SOL 100MG/ML — 20
    EPIDIOLEX QL20 mL every 1 day (100 mg/mL)
    FINTEPLA QL12 mL every 1 day (2.2 mg/mL)
    ContextCannabidiol/related solutions with daily mL QLs
    inv-167: lacosamide tabs — 2
    Lacosamide QL2 tabs every 1 day
    Strengths50–200 mg strengths listed with QL 2/day
    ProductLacosamide (Vimpat) generic entries
    inv-168: pregabalin caps (various strengths) — 2-4
    Pregabalin QL range2–4 caps every 1 day depending on strength
    Examples75/100/150 mg: 4/day; 200 mg: 3/day; 225/300 mg: 2/day
    Product classPregabalin (various strengths) entries
    inv-173: ZTALMY SUS 50MG/ML — 1,100
    ZTALMY suspension QL1,100 mL every 30 days
    ProductZTALMY SUS 50 mg/mL
    AuthorizationPA indicated for ZTALMY entries
    inv-174: XCOPRI packs and tablets — 1-2
    XCOPRI QL1–2 tabs per day depending on pack/strength
    ProductsXCOPRI PAK and tablet strengths list per-day QLs and PA
    NoteSome pack/strength combinations have different QLs (1 vs 2/day)
    inv-175: TRINTELLIX (5-20 mg) — 1
    TRINTELLIX QL1 tab every 1 day
    RequirementsST and PA for new starts are indicated
    Strengths5–20 mg tablet strengths listed
    inv-176: citalopram solution/tab — specified daily limits
    Citalopram solution/tab QL30 mL solution or 6 tabs (10 mg) or 3 tabs (20 mg) per day as specified
    ProductsCitalopram oral solution 10 mg/5 mL and tablet strengths
    NotesHigher-strength tablet daily equivalents shown in QL mapping
    inv-177: duloxetine capsules (20,30,60 mg) — 2
    Duloxetine QL2 caps every 1 day
    Strengths20, 30, 60 mg capsule strengths listed
    ReferenceSSRI/SNRI section QLs
    inv-178: desvenlafaxine ER — 1
    Desvenlafaxine QL1 tab every 1 day
    Strengths25, 50, 100 mg ER formulations listed
    ContextSNRI class QLs noted
    inv-179: phenytoin chewable tab 50 mg — Age limit Max 12
    Phenytoin chewable age limitAge Max 12
    ProductPhenytoin chewable tablet 50 mg (Dilantin Infatabs)
    DocumentationAge limit should be documented when prescribing
    inv-180: vilazodone — 1
    Vilazodone QL1 tab every 1 day
    Strengths10, 20, 40 mg tablet strengths listed
    ContextAntidepressant entries list per-day QLs
    inv-181: dapagliflozin-metformin 5-1000 mg — 2 tabs
    Dapagliflozin-metformin 5-1000 QL2 tabs every 1 day
    Dapagliflozin-metformin 10-1000 QL1 tab every 1 day
    RequirementST and PA indicated for these combination ER products
    inv-183: MOUNJARO pens — 4 pens
    MOUNJARO pens QL4 pens every 28 days
    OZEMPIC pens QL1 pen every 28 days
    AuthorizationPA and ST apply; PA for new starts noted for MOUNJARO
    inv-184: OZEMPIC pens — 1 pen
    OZEMPIC pen QL1 pen every 28 days
    Applies toOzempic injectable pens (various strengths)
    ControlsST, PA, QL indicated on product rows
    inv-185: RYBELSUS tablets — 30 tabs
    RYBELSUS QL30 tabs every 180 days (for select strengths)
    Alternate QLsSome strengths list 1 tab every day or 30 tabs/180 days as specified
    RequirementST and PA indicated for many oral semaglutide strengths
    inv-186: Insulin glargine products — 1-2 mL
    Insulin glargine QL1–2 mL every 1 day depending on product
    ProductsInsulin glargine products and other insulin formulations listed with mL/day QLs
    NotesSome insulin products also list PA or OTC status depending on formulation
    inv-187: TRULICITY pens — 4 pens
    TRULICITY pens QL4 pens every 28 days
    Applies toTrulicity injectable pens multiple strengths
    AuthorizationPA indicated on product rows
    inv-188: ondansetron oral soln 4 mg/5ml — 50 mL
    Ondansetron solution QL50 mL every 30 days
    Ondansetron 24 mg QL6 tabs every 30 days (Max 2 fills every 30 days)
    Context5-HT3 antagonist entries list solution and tablet limits
    inv-189: ondansetron 24 mg tab — 6 tabs
    Ondansetron 24 mg QL6 tabs every 30 days (Max 2 fills every 30 days)
    AKYNZEO QL2 caps every 21 days
    DICLEGIS QL4 tabs every 1 day
    inv-190: AKYNZEO CAP 300-0.5 — 2 caps
    AKYNZEO QL2 caps every 21 days
    DICLEGIS QL4 tabs every 1 day (doxylamine-pyridoxine)
    ContextAntiemetic product rows with PA/QL as specified
    inv-192: CRESEMBA CAP 74.5MG — 5 caps
    CRESEMBA QL5 caps every 1 day (74.5 mg) or 2 caps/day for alternate strength
    VIVJOA QL18 caps every 365 days (150 mg)
    PAPA and QL apply to these antifungal entries
    inv-193: VIVJOA CAP 150MG — 18 caps
    VIVJOA QL18 caps every 365 days
    Strength150 mg formulation listed with annual QL
    PAPA indicated for VIVJOA
    inv-194: TRYVIO TAB 12.5MG — 1
    TRYVIO QL1 tab every 1 day
    AuthorizationPA indicated for TRYVIO product row
    Product classEndothelin receptor antagonist entry
    inv-195: FIRDAPSE TAB 10MG — 10
    FIRDAPSE QL10 tabs every 1 day
    ProductFIRDAPSE (amifampridine) 10 mg
    AuthorizationPA indicated in product row
    inv-196: pyrimethamine 25 mg — 3
    Pyrimethamine QL3 tabs every 1 day
    Strength25 mg tablet entry
    ContextAntimalarial/antiparasitic entries list PA/QL as applicable
    inv-197: ONUREG TAB 200/300MG — 14
    ONUREG QL14 tabs every 28 days
    StrengthsONUREG 200 mg and 300 mg both list 14 tabs per 28 days
    AuthorizationPA indicated for ONUREG entries
    inv-198: FRUZAQLA CAP 1MG — 84
    FRUZAQLA QL (1 mg)84 caps every 28 days
    FRUZAQLA QL (5 mg)21 caps every 28 days
    AuthorizationPA required for FRUZAQLA entries
    inv-199: INLYTA TAB 1MG — 8
    INLYTA 1 mg QL8 tabs every 1 day
    INLYTA 5 mg QL4 tabs every 1 day
    AuthorizationPA and QL listed for INLYTA strengths
    inv-202: LENVIMA — strength-specific caps/day limits
    LENVIMA caps QLStrength-specific: 1–3 caps per day depending on strength
    Examples4 mg: 1/day; 8 mg: 2/day; 12 mg: 3/day
    AuthorizationPA required for Lenvima entries
    inv-203: capecitabine — 4 tabs/day (150 mg) or 10 tabs/day (500 mg)
    Capecitabine QL4 tabs/day (150 mg) or 10 tabs/day (500 mg)
    Applies toCapecitabine tablet formulations listed in antimetabolites section
    AuthorizationPA noted for capecitabine in product rows
    inv-215: Example entries aggregated — assorted QL examples
    Example aggregated QLsExamples include 14 tabs every 28 days; 1–3 caps every day; 42 tabs every 28 days
    ContextAggregated from multiple oncology product rows showing PA and QL
    Provider noteClaims may be denied without PA or if QL exceeded
    inv-216: ropinirole hydrochloride ER — QL 1 tab every 1 day
    Ropinirole ER QL1 tab every 1 day for listed ER strengths
    Applies toRopinirole hydrochloride ER 2–12 mg strengths
    ContextAntiparkinson adjunctive therapy listings show per-day ER QLs

    Policy Background and Scope

    This section of the formulary enumerates multiple analgesic drug categories and places them in the plan formulary context with tier assignments and utilization controls. Categories represented include nonsteroidal anti‑inflammatory drugs (NSAIDs) such as naproxen and meloxicam, PDE4 inhibitors (e.g., OTEZLA), soluble TNF receptor agents (ENBREL), and a range of opioid agonists and partial agonists with product‑specific quantity and age limits.

    The formulary entries show that many analgesic and related agents are assigned to Tier 1 or Tier 2 and that utilization management is applied per product: Prior Authorization (PA) and Quantity Limits (QL)QL = 55 tabs/28 days), while some OTC analgesics (e.g., naproxen sodium 220 mg) are marked OTC and not subject to PA/QL enforcement in these listings. Opioid lines specifically include age and quantity controls (e.g., fentanyl patches with QL = 10 patches/30 days), reflecting safety controls for that class.

    Glossary and Abbreviations

    inv-107: Age Limit — AGE
    AGEAge Limit (AGE) indicated on product rows where applicable
    ExamplePhenytoin chewable tab 50 mg: Age Max 12; many opioid entries list Age Min 18
    PurposeAge limits are enforced alongside QL and PA as specified
    inv-108: Prior Authorization — PA
    PAPrior Authorization — required when listed on product row (PA)
    ImplicationClaims submitted without required PA may be denied or delayed
    DocumentationProviders must supply supporting documentation for PA where indicated
    inv-109: Quantity Limit — QL
    QLQuantity Limit — specified amount per day or per 28 days (QL)
    ExamplesCommon QLs include '1 tab every 1 day', '4 pens every 28 days', '55 tabs every 28 days'
    EnforcementExceeding QL may require PA or result in denial
    inv-110: Prior Authorization (alternate reference)
    PA (alt ref)Prior Authorization (PA) — see product Requirements/Limits for PA status
    EffectPA frequently paired with QL and ST for specialty agents
    Provider actionObtain PA before dispensing if listed
    inv-111: Quantity Limit (alternate reference)
    QL (alt ref)Quantity Limit — amount per day or per 28 days as specified on product rows
    MeasurementQL values presented in units: tabs, caps, pens, mL, syringes, inhalers
    EnforcementPharmacy systems enforce QL based on these values
    inv-112: PA — Prior Authorization
    PA definitionPA — Prior Authorization is a utilization control requiring approval before coverage
    When usedApplied to many branded, specialty, and some generic products in this formulary
    OutcomeClaims may be denied without approved PA
    inv-113: QL — Quantity Limit (amount per day or per 28 days)
    QL definitionQL — Quantity Limit (specified as amount per day or per 28 days)
    FormatPresented as 'X units every Y days' or 'X units every 1 day' in product rows
    EnforcementClaims exceeding QL require PA justification or may be denied
    inv-114: Tier — Formulary drug tier assignment (Tier 1 / Tier 2)
    TierFormulary drug tier assignment (Tier 1 / Tier 2)
    UseTier determines member cost-sharing and may be shown per product row
    ExamplesMany generics Tier 1; many branded/specialty Tier 2